The Next Era in Non-Factor Therapy for Hemophilia: Clinical Evidence and Practical Implications of Evolving FVIIIA Mimetics

August 15, 2026

Hemophilia care continues to evolve with the emergence of new therapies that offer transformative alternatives to traditional treatment approaches. This activity focuses on the latest clinical evidence surrounding FVIIIa mimetic therapies, including mechanisms of action, pharmacokinetics, dosing strategies, and their practical implications in patient care. Data from pivotal trials will be examined, along with guidance for incorporating these agents into everyday clinical practice. Through interactive, case-based scenarios, learners will develop a deeper understanding of patient selection, treatment sequencing, and individualized management strategies equipping clinicians with the tools needed to optimize outcomes in hemophilia care.

Target Audience

This educational activity is intended for pediatric and adult hematologists, hematologists/oncologists, hematology and hematology/oncology APPs, and other HCPs involved in the management of people living with hemophilia

Learning Objectives

Upon completion of this activity, the learner should be able to:

  • Describe structural and pharmacokinetic (PK)/pharmacodynamic (PD) distinctions, and the related impact on dosing, between available and emerging FVIIIa mimetics
  • Assess efficacy and safety evidence on emerging FVIIIa mimetics as prophylaxis across varying hemophilia patient populations
  • Develop treatment plans with people living with hemophilia A (PLwHA) that incorporate FVIIIa mimetic therapies, considering initiation, switching, and monitoring protocols
  • Recognize strategies that align with shared decision making (SDM) principles to engage PLwH in individualized goal setting, treatment selection, and long-term adherence and compliance

Commerical Support
This activity is supported by an educational grant from Novo Nordisk.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 1.25 ACPE Pharmacist

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 contact hours.

  • 1.25 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC Contact Hours

    Credit being awarded: 1.25 ANCC contact hours

  • 1.25 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

Course opens: 
07/31/2026
Course expires: 
10/15/2026
Event starts: 
08/15/2026 - 7:35am EDT
Event ends: 
08/15/2026 - 8:50am EDT
Cost:
$0.00
Add to calendar: 
Rating: 
0
Canary 3-4 Ballroom , Orlando World Center MarriottOrlando, FL
Orlando, FL
United States

Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH Inc. prior to accreditation of the activity.

Staff/Reviewers
Alexandra E. Marsillo, PhD, Catalyst Medical Education, LLC, Medical Director, has no financial relationships to disclose.
Louis Settembrino, CHCP, Catalyst Medical Education, LLC, President and CEO, has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Inc., President, Planner, has no financial relationships to disclose.
Rebecca Lakofsky, BSN, RN, AKH Inc., Planner/Reviewer, has no financial relationships to disclose.
Trish Brignoni, AKH Inc., Associate VP, has no financial relationships to disclose.
AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC, planners and reviewers have no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional and, therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants’ misunderstanding of the content. If you would like to opt out from future communications from AKH Inc., please send an email to [email protected] with your information with “Opt Out” in the subject line.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the U.S. Food and Drug Administration (FDA). Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Committee Member, Planner, Staff(s)

Jenny Mcdaniel, MD

has a financial relationship (Advisor) with Hema Biologics;.
has a financial relationship (Advisor) with Sanofi;.
has a financial relationship (Advisor) with Pfizer;.

Guy Young, MD

has a financial relationship (Consultant) with Pfizer;.
has a financial relationship (Consultant) with Alnylam;.
has a financial relationship (Consultant) with Takeda;.
has a financial relationship (Consultant) with Sanofi;.
has a financial relationship (Consultant) with Octapharma;.
has a financial relationship (Consultant) with Novo Nordisk;.
has a financial relationship (Consultant) with Hemab;.
has a financial relationship (Consultant) with Hema Biologics;.
has a financial relationship (Consultant) with Genentech;.
has a financial relationship (Consultant) with CSL;.
has a financial relationship (Consultant) with Biomarin;.
Speaker, Instructor, Faculty(s)

Jenny Mcdaniel, MD

has a financial relationship (Advisor) with Pfizer;.
has a financial relationship (Advisor) with Sanofi;.
has a financial relationship (Advisor) with Hema Biologics;.

Guy Young, MD

has a financial relationship (Consultant) with Novo Nordisk;.
has a financial relationship (Consultant) with Octapharma;.
has a financial relationship (Consultant) with Pfizer;.
has a financial relationship (Consultant) with Sanofi;.
has a financial relationship (Consultant) with Takeda;.
has a financial relationship (Consultant) with Hemab;.
has a financial relationship (Consultant) with Hema Biologics;.
has a financial relationship (Consultant) with Genentech;.
has a financial relationship (Consultant) with CSL;.
has a financial relationship (Consultant) with Biomarin;.
has a financial relationship (Consultant) with Alnylam;.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Available Credit

  • 1.25 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 1.25 ACPE Pharmacist

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 contact hours.

  • 1.25 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC Contact Hours

    Credit being awarded: 1.25 ANCC contact hours

  • 1.25 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

Price

Cost:
$0.00
Please login or register to take this course.

Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].